Adjuvant radioiodine treatment in patients with thyroid cancer – current recommendations

Radioactive iodine (RAI) has been used for the postsurgical treatment of differentiated thyroid cancer (DTC) for over 50 years. Its therapeutic application in DTC is related to the ability of thyroid cells (both normal and cancerous) to actively capture iodine, including RAI, which is a β radiation emitter [1]. The incorporation of RAI into a thyrocyte cell leads to the formation of free radicals that damage the DNA structure and contribute to cell death or loss of its growth and division potential. For many years, radioiodine treatment was routinely recommended as an adjunct to surgery regardless of the disease recurrence or death risk.Radioactive iodine therapy (RAI) has been used in patients with differentiated thyroid cancers (DTC) for many decades.However, many changes in thyroid cancer treatment have been introduced for the last decade worldwide, mainly atendency to deescalate both surgical and adjuvant treatment has been observed. This work summarizes current Polishguidelines for adjuvant radioiodine therapy compared to American Thyroid Association recommendations